Brainstorm Cell Therapeutics Inc
BCLI1.170USD
-0.030-2.50%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
9.26MCap. mercado
PérdidaP/E TTM
Más Datos de Brainstorm Cell Therapeutics Inc Compañía
BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.
Información de la empresa
Símbolo de cotizaciónBCLI
Nombre de la empresaBrainstorm Cell Therapeutics Inc
Fecha de salida a bolsaMay 28, 2003
Director ejecutivoMr. Chaim Lebovits
Número de empleados27
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 28
Dirección1325 Avenue Of Americas
CiudadNEW YORK
Bolsa de valoresUS 'Other OTC' and Grey Market
PaísUnited States of America
Código postal10019
Teléfono12014880460
Sitio Webhttps://brainstorm-cell.com/
Símbolo de cotizaciónBCLI
Fecha de salida a bolsaMay 28, 2003
Director ejecutivoMr. Chaim Lebovits
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+919.54%
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+3833.25%
Dr. Ibrahim B. (Bob) Dagher, M.D.
Dr. Ibrahim B. (Bob) Dagher, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
Director
Director
--
--
Prof. Jacob A. Frenkel, Ph.D.
Prof. Jacob A. Frenkel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Menghisteab (Menghis) Bairu, M.D.
Dr. Menghisteab (Menghis) Bairu, M.D.
Independent Director
Independent Director
--
--
Dr. Anthony John (Tony) Polverino, Ph.D.
Dr. Anthony John (Tony) Polverino, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+919.54%
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+3833.25%
Dr. Ibrahim B. (Bob) Dagher, M.D.
Dr. Ibrahim B. (Bob) Dagher, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 27 de jul
Actualizado: dom., 27 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Armistice Capital LLC
8.70%
Ruck (Matthew J)
3.47%
Ness (Kevin Dean)
2.57%
Lebovits Chaim
2.53%
Caldwell Sutter Capital, Inc
1.98%
Other
80.75%
Accionistas
Accionistas
Proporción
Armistice Capital LLC
8.70%
Ruck (Matthew J)
3.47%
Ness (Kevin Dean)
2.57%
Lebovits Chaim
2.53%
Caldwell Sutter Capital, Inc
1.98%
Other
80.75%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
14.30%
Hedge Fund
9.03%
Investment Advisor
3.58%
Holding Company
1.68%
Investment Advisor/Hedge Fund
0.73%
Research Firm
0.04%
Other
70.63%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
115
2.33M
29.37%
+771.43K
2025Q1
116
2.29M
28.90%
+743.86K
2024Q4
114
1.19M
21.02%
-226.10K
2024Q3
109
1.22M
22.61%
-265.31K
2024Q2
109
1.32M
25.54%
+439.02K
2024Q1
108
855.32K
19.26%
-132.87K
2023Q4
109
841.70K
26.44%
-125.02K
2023Q3
116
902.82K
33.14%
-178.28K
2023Q2
123
1.03M
39.20%
+17.38K
2023Q1
150
979.29K
38.21%
+5.81K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Armistice Capital LLC
690.67K
8.7%
+690.67K
--
Mar 31, 2025
Ruck (Matthew J)
275.84K
3.47%
+275.84K
--
Nov 13, 2024
Ness (Kevin Dean)
204.00K
2.57%
-40.00K
-16.39%
Feb 14, 2024
Lebovits Chaim
200.96K
2.53%
--
--
Apr 01, 2025
Caldwell Sutter Capital, Inc
157.01K
1.98%
--
--
Mar 31, 2025
ACC International Holdings, Ltd.
133.39K
1.68%
--
--
Apr 01, 2025
Dagher (Ibrahim B.)
79.52K
1%
--
--
Apr 01, 2025
Yablonka (Uri)
68.46K
0.86%
--
--
Apr 01, 2025
Geode Capital Management, L.L.C.
58.16K
0.73%
+5.66K
+10.79%
Mar 31, 2025
Hartounian (Hartoun)
52.00K
0.66%
--
--
Apr 01, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
Fecha
Tipo
Relación
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
